Daiichinkyo Co (TSE:4568) Machinery, Furniture, Equipment : 円0 Mil (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Machinery, Furniture, Equipment?

Daiichinkyo Co's Machinery, Furniture, Equipment for the quarter that ended in Mar. 2024 was 円0 Mil.

Daiichinkyo Co Machinery, Furniture, Equipment Historical Data

The historical data trend for Daiichinkyo Co's Machinery, Furniture, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Machinery, Furniture, Equipment Chart

Daiichinkyo Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Machinery, Furniture, Equipment

Get a 7-Day Free Trial

Daiichinkyo Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Machinery, Furniture, Equipment	Get a 7-Day Free Trial															-	-	-	-	-

Daiichinkyo Co Machinery, Furniture, Equipment Calculation

Machinery, Furniture, Equipment represents those fixed assets specifically dealing with tools, equipment and office furniture.

Daiichinkyo Co (TSE:4568) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (TSE:4568) » Definitions » Machinery, Furniture, Equipment

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (TSE:4568) Headlines

No Headlines